UNOVARTIS

SCEMBLIX - Patient monitoring and management - HCP

Prescribing information

Image



Image




SCEMBLIX® $\mathbf{\nabla}$ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.¹

Patient monitoring and management

Regular monitoring is important to assess treatment benefits and inform the decision to ${\rm switch}^{2,3}$

Monitoring milestones of BCR-ABL1 transcript levels by the IS (international scale) at 3, 6 and 12 months is essential to determine treatment interventions.^{2,3}





Adapted from Hocchaus A, et al. 2020 and Smith G, et al. 2020.^{2,3}

For full details on monitoring, please see the ELN 2020 Guidelines and the SCEMBLIX SmPC.

Even after MMR is achieved, monitoring of MMR should continue every 3-6 months^{2,3}

Make monitoring and management effective

Visit our resources pages for patient support tools

BCR-ABL, breakpoint cluster region and Abelson murine leukaemia viral oncogene homologue; CCyR, complete cytogenetic remission; EMR, early molecular response; IS, international scale; MMR, major molecular response; MR, molecular response.

For further information, please refer to the **<u>Summary of Product Characteristics</u>**.

References:

- 1. SCEMBLIX (asciminib) Summary of Product Characteristics.
- 2. Hochhaus A, et al. *Leukemia* 2022;34:996-984.
- 3. Smith G, et al. Br J Haematol 2020;191(2):171-193.

UK | November 2024 | FA-11311678

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <u>www.novartis.com/report</u>, or alternatively email <u>medinfo.uk@novartis.com</u> or call 01276 698370.

Source URL:

https://www.pro.novartis.com/uk-en/medicines/haematology/scemblix/patient-monitoring